CRH Medical posted revenues of $29.1 million for the first quarter of 2019.
Exact Sciences posted first-quarter 2019 revenues of $162 million, a 79 percent year-over-year increase.
For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.
Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.
More articles on gastroenterology:
2 Texas clinicians unintentionally compromise patient information — 6 insights
AGA joins ‘Let My Doctor Decide’ to fight step therapy
Motus readies for commercial launch of Pure-Vu, posts $5.2M net loss for Q1 — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
